Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...
Clinical Trials Arena on MSN
Compass Therapeutics’s stock crashes after OS miss in BTC trial
Compass Therapeutics will still submit tovecimig for approval despite the OS miss.
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results